Table 3 Cox proportional hazards analysis of overall survival based on biomarker combination in the validation cohort
| Â | Variable | Univariable Cox regression | Multivariable Cox regression using AR aberration and 3-lipid signature | Multivariable Cox regression using TP53 aberration and 3-lipid signature | Multivariable Cox regression using RB1 deletion and 3-lipid signature | Multivariable Cox regression using PI3K aberration and 3-lipid signature | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
Biomarker combinations | AR aberration and/or 3-lipid signature (Groups 1 and 2 vs 0) | 2.92 (1.79–4.75) | < 0.001 | 2.45 (1.42–4.20) | 0.001 | – | – | – | – | – | – |
TP53 aberration and/or 3-lipid signature (Groups 1 and 2 vs 0) | 2.77 (1.67–4.61) | < 0.001 | – | – | 2.82 (1.64–4.83) | < 0.001 | – | – | – | – | |
RB1 deletion and/or 3-lipid signature (Groups 1 and 2 vs 0) | 2.53 (1.58–4.07) | < 0.001 | – | – | – | – | 1.95 (0.98–3.86) | < 0.001 | – | – | |
PI3K aberration and 3-lipid signature (Group 2 vs 0 and 1) | 1.78 (1.03–3.10) | 0.04 | – | – | – | – | – | – | 1.32 (0.70–2.50) | 0.396 | |
Clinicopatholgic factors | PSA, ng/mLa | 1.00 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | < 0.001 | 1.00 (1.00–1.00) | < 0.001 |
ALP, IU/La | 1.00 (1.00–1.00) | 0.002 | 1.00 (1.00–1.00) | 0.024 | 1.00 (1.00–1.00) | 0.03 | 1.00 (1.00–1.00) | 0.069 | 1.00 (1.00–1.00) | 0.034 | |
ctDNA Fraction | ctDNA fraction > 2% | 1.91 (1.18–3.08) | 0.008 | 1.29 (0.76–2.17) | 0.347 | 1.37 (0.81–2.30) | 0.238 | 1.74 (1.05–2.87) | 0.062 | 1.67 (1.01–2.78) | 0.048 |